Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report

Case Reports in Oncology

卷:14

Nam Bui¹  Seema Nagpal²  Tyler Lanman³  Melanie Hayden Gephart⁴  Angus Toland⁵ 

[1] Department of Medicine, Oncology, Stanford University, Stanford, CA, USA;

[2] Department of Neurology, Neuro-Oncology, Stanford University, Stanford, CA, USA;

[3] Department of Neurology, Stanford University, Stanford, CA, USA;

[4] Department of Neurosurgery, Stanford University, Stanford, CA, USA;

[5] Department of Pathology, Stanford University, Stanford, CA, USA;

关键词: neurotrophic tropomyosin receptor kinase;    leptomeningeal disease;    brain metastases;    larotrectinib;    uterine sarcoma;   

DOI  :  10.1159/000521158

来源: DOAJ

【 摘 要 】

While neurotrophic tropomyosin receptor kinase (NTRK) fusions represent rare oncogenic drivers (<1% of solid cancers), the recent approval of NTRK inhibitors (larotrectinib and entrectinib) led to dramatic responses in patients with NTRK fusion+ tumors. Both drugs have phase I data, demonstrating efficacy in the central nervous system (CNS), including both primary brain tumors and brain metastases. We present a 29-year-old woman who was diagnosed with NTRK3-SPECC1L fusion+ undifferentiated uterine sarcoma and underwent resection, chemotherapy, and radiotherapy. Two years later, lung metastases were discovered. She was started on larotrectinib with complete response. She remained stable on larotrectinib until she presented with altered mental status and seizures. MRI demonstrated leptomeningeal enhancement, but because leptomeningeal progression from sarcoma is exceedingly rare and her symptoms improved dramatically with antiepileptics, these findings were initially attributed to seizures. After 2 unrevealing lumbar punctures and stable systemic imaging, a brain biopsy demonstrated metastatic sarcoma, still showing NTRK positivity. She underwent whole brain radiotherapy and was switched to entrectinib, but had clinical progression 1 month later and transitioned to hospice. This case demonstrates the efficacy of NTRK inhibitors in rare and aggressive cancer but highlights that these patients can develop isolated CNS progression even in the setting of CNS-penetrant drugs. CNS progression can occur if there is incomplete CNS drug penetration, discordance in molecular profiles between CNS and systemic disease, or acquired NTRK inhibitor resistance. In this case, CNS disease maintained the NTRK fusion status, but either inadequate CNS penetration or development of a resistance gene may explain the isolated CNS progression.

【 授权许可】

Unknown